ReviewImmunological reviews2017
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
Review in Immunological reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.EBioMedicine · 2022Pooled it
- Effects of sex but not race and geographic origin on vaccine-induced HIV-specific antibody responses.Frontiers in immunology · 2025Trial
- Trial
- Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.mSphere · 2020Trial
- Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.The Journal of clinical investigation · 2019Trial
- Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.Science translational medicine · 2019Trial
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).Lancet (London, England) · 2018Trial
- Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.The Journal of infectious diseases · 2018Trial
- Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.Human vaccines & immunotherapeutics · 2018Trial
- Human immunodeficiency virus vaccines: Advances, challenges and future perspectives.World journal of virology · 2026Review
- T cell antigenic recognition sequencing (TAR-seq) enables precise characterization of vaccine-elicited cellular immunity ex vivo andFrontiers in immunology · 2026Article
- A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.Emerging microbes & infections · 2025Article
- Integrating Cellular Immune Biomarkers with Machine Learning to Identify Potential Correlates of Protection for aVaccines · 2025Article
- Article
- Review
- Review
- Review
- Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.Viruses · 2024Review
- Prophylactic HIV-1 vaccine trials: past, present, and future.The lancet. HIV · 2024Review
- Absolute quantitation of binding antibodies from clinical samples.NPJ vaccines · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Development of an efficacious HIV-1 vaccine is a major priority for improving human health worldwide. Vaccine-mediated protection against human pathogens can be achieved through elicitation of protective innate, humoral, and cellular responses. Identification of specific immune responses responsible for pathogen protection enables vaccine development and provides insights into host defenses against pathogens and the immunological mechanisms that most effectively fight infection. Defining immunological correlates of transmission risk in preclinical and clinical HIV-1 vaccine trials has moved the HIV-1 vaccine development field forward and directed new candidate vaccine development. Immune correlate studies are providing novel hypotheses about immunological mechanisms that may be responsible for preventing HIV-1 acquisition. Recent results from HIV-1 immune correlates work has demonstrated that there are multiple types of immune responses that together, comprise an immune correlate-thus implicating polyfunctional immune control of HIV-1 transmission. An in depth understanding of these complex immunological mechanisms of protection against HIV-1 will accelerate the development of an efficacious HIV-1 vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.